Efficacy of andrographolide in not active progressive multiple sclerosis: a prospective exploratory double-blind, parallel-group, randomized, placebo-controlled trial

Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial

(2020) Jeremy Chataway et al.   LANCET NEUROLOGY

Epidemiology and treatment of multiple sclerosis in elderly populations

(2019) Caila B. Vaughn et al.   Nature Reviews Neurology

A double‐blind, randomized, placebo‐controlled study to assess the efficacy of Andrographis paniculata standardized extract (ParActin®) on pain reduction in subjects with knee osteoarthritis

(2019) Juan L. Hancke et al.   PHYTOTHERAPY RESEARCH

The neuroprotective activities of natural products through the Nrf2 upregulation

(2019) Alireza Tavakkoli et al.   PHYTOTHERAPY RESEARCH

The effect of emerging nutraceutical interventions for clinical and biological outcomes in multiple sclerosis: A systematic review

(2019) Wolfgang Marx et al.   Multiple Sclerosis and Related Disorders

Evaluation of the effect of andrographolide and methotrexate combined therapy in complete Freundʼs adjuvant induced arthritis with reduced hepatotoxicity

(2018) Fenfen Li et al.   BIOMEDICINE & PHARMACOTHERAPY

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

(2018) Ludwig Kappos et al.   LANCET

Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis

(2018) Robert J. Fox et al.   NEW ENGLAND JOURNAL OF MEDICINE

Determination of Bitterness of Andrographis Herba Based on Electronic Tongue Technology and Discovery of the Key Compounds of Bitter Substances

(2018) Xiao Zhang et al.   MOLECULES

Multiple sclerosis

(2018) Massimo Filippi et al.   Nature Reviews Disease Primers

Andrographolide attenuates microglia-mediated Aβ neurotoxicity partially through inhibiting NF-κB and JNK MAPK signaling pathway

(2017) Rui Yang et al.   IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY

Andrographolide - A promising therapeutic agent, negatively regulates glial cell derived neurodegeneration of prefrontal cortex, hippocampus and working memory impairment

(2017) Sudeshna Das et al.   JOURNAL OF NEUROIMMUNOLOGY

Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function

(2017) Daniel Ontaneda et al.   LANCET

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

(2017) Xavier Montalban et al.   NEW ENGLAND JOURNAL OF MEDICINE

Andrographis paniculata (Chuān Xīn Lián) for symptomatic relief of acute respiratory tract infections in adults and children: A systematic review and meta-analysis

(2017) Xiao-Yang Hu et al.   PLoS One

Andrographis paniculata decreases fatigue in patients with relapsing-remitting multiple sclerosis: a 12-month double-blind placebo-controlled pilot study

(2016) J. C. Bertoglio et al.   BMC Neurology

Andrographolide Stimulates Neurogenesis in the Adult Hippocampus

(2015) Lorena Varela-Nallar et al.   NEURAL PLASTICITY

Andrographolide reduces cognitive impairment in young and mature AβPPswe/PS-1 mice

(2015) Felipe G Serrano et al.   Molecular Neurodegeneration

Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial

(2014) Jeremy Chataway et al.   LANCET

Defining the clinical course of multiple sclerosis: The 2013 revisions

(2014) F. D. Lublin et al.   NEUROLOGY

Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria

(2011) Chris H. Polman et al.   ANNALS OF NEUROLOGY

Andrographolide Inhibits PI3K/AKT-Dependent NOX2 and iNOS Expression Protecting Mice against Hypoxia/Ischemia-Induced Oxidative Brain Injury

(2011) Chang-Ming Chern et al.   PLANTA MEDICA

Neuroprotective effects of andrographolide in a rat model of permanent cerebral ischaemia

(2010) Su Jing Chan et al.   BRITISH JOURNAL OF PHARMACOLOGY

Sample sizes for brain atrophy outcomes in trials for secondary progressive multiple sclerosis

(2008) D. R. Altmann et al.   NEUROLOGY